May 2024

STOCKHOLM, May 24, 2024 /PRNewswire/ — A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic ki

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: